Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Evidence Based Medicine presented by InpharmD™ · InpharmD™
September 28, 20217m 33s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A randomized, double-blind, parallel-group, placebo-controlled, event-driven trial conducted to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes in patients with heart failure and a preserved ejection fraction.